This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 21, 2019
Components Enhance High Volume Injectable Drug Delivery Systems
Author(s)BioPharm International Editors
West introduced NovaPure 3-mL Cartridge components and the SmartDose Gen. II 10-mL injector.
Advertisement
West Pharmaceutical Services launched NovaPure 3-mL Cartridge components, which are plunger and lined-seal components designed for consistent delivery for higher-volume injectable drug delivery systems. The company also announced that the SmartDose Gen. II 10-mL injector, for subcutaneous delivery of up to 10-mL in volume, is now available for commercialization.
The cartridge components expand the NovaPure product portfolio, which already included stoppers and syringe plungers. NovaPure components are produced with quality principles that result in dimensional control and consistency, vision inspection and visible particulate control, and quality particle specification. The new components are specifically designed for 3-mL cartridges often used in autoinjectors and other drug delivery devices. They incorporate West’s Westar pharmaceutical wash and sterilization, FluroTec barrier film, and a comprehensive data package, and they are suitable for sensitive biologic drugs coming to market.
West’s SmartDose portfolio of devices enables home-based drug administration for injectables. The SmartDose Gen. II 10-mL drug delivery system adheres to the patient's body, so patients can remain hands-free during the injection, which may range from minutes to hours. The company has now completed the development work to enable up to 10-mL of medication injection.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5